Author:
Clerico Michele,Ferrero Simone,Alessandria Beatrice,Zaccaria Gian Maria,Genuardi Elisa,Ragaini Simone,Tavarozzi Rita,Cavallo Federica,Hohaus Stefan,Musuraca Gerardo,Carella Angelo Michele,Stelitano Caterina,Tani Monica,Gaidano Gianluca,Olivieri Jacopo,Usai Sara Veronica,Galimberti Sara,Re Francesca,Mian Michael,Castellino Claudia,Pavone Vincenzo,Evangelista Andrea,Bruno Benedetto,Cortelazzo Sergio,Passera Roberto,Ladetto Marco
Publisher
Springer Science and Business Media LLC
Reference20 articles.
1. Swerdlow, S.H. World Health Organization, International Agency for Research on Cancer. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/WHO-Classification-Of-Tumours-Of-Haematopoietic-And-Lymphoid-Tissues-2017. Accessed October 6, 2022.
2. Le Gouill, S. et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N. Engl. J. Med. 377(13), 1250–1260. https://doi.org/10.1056/nejmoa1701769 (2017).
3. Dreyling, M. et al. Efficacy and safety of ibrutinib combined with standard first-line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: Results from the randomized triangle trial by the European MCL network. Blood. 140(Supplement 1), 1–3. https://doi.org/10.1182/blood-2022-163018 (2022).
4. Ladetto, M. et al. Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: Results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial. Lancet Haematol. 8(1), e34–e44. https://doi.org/10.1016/S2352-3026(20)30358-6 (2021).
5. Ferrero, S. et al. Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma. Blood. 140(12), 1378–1389. https://doi.org/10.1182/blood.2021014270 (2022).